Inmed announces update on phase 2 clinical trial investigating inm-755 cannabinol cream for epidermolysis bullosa

Vancouver, british columbia, july 25, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug inm-755 cannabinol (“cbn”) cream for the treatment of patients with epidermolysis bullosa (“eb”).
INM Ratings Summary
INM Quant Ranking